Shilpa Medicare

Shilpa Pharma Lifesciences Limited receives CEP from EDQM for Octreotide API

This marks the second peptide molecule in Shilpa's expanding peptide portfolio.

Shilpa Medicare shares surge 4% on strong Q2 FY25 financial performance

Stock to Watch: Shilpa Medicare reports robust Q2 FY25 performance with 11% revenue growth and 1008% PAT increase

Shilpa Medicare announces USFDA acceptance of NDA for Oxylanthanum Carbonate filed by Unicycive

Shilpa Medicare shares jump 3% as CDMO customer secures USFDA Fast Track Designation for GBM Drug

Shilpa Medicare shares surge over 2% after arm gets CEP from EDQM for Desmopressin

Shilpa Pharma Lifesciences receives CEP for Desmopressin from EDQM

Shilpa Medicare shares rise 4% to after Antique initiates ‘Buy’ rating with target price of ₹1300

Shilpa Medicare Stock: Share price surges 9% this week on USFDA approval for Bortezomib Injection

Shilpa Medicare gets USFDA approval for Bortezomib Injection

Shilpa Medicare reports successful outcome of Phase 3 studies of SMLNUD07 – NorUDCA

Shilpa Medicare shares rise 3% after subsidiary receives GMP certification from Mexico

MSCI review: Delhivery added, Shilpa Medicare deleted from smallcap index

All modifications will become effective on February 28, 2023.

Shilpa Medicare shares rise as it launches anti-cancer drug